ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 257.0 | 218.3 | 198.0 |
| Other income | 11.2 | 18.5 | 12.1 |
| Total income | 268.2 | 236.7 | 210.1 |
| Profit before exceptional items & tax | 44.9 | 43.4 | 23.4 |
| Exceptional items | 0.0 | -2.5 | 0.0 |
| Profit before tax | 44.9 | 40.9 | 23.4 |
| Net profit | 37.0 | 24.8 | 16.7 |
| Operating margin | 16.7% | 17.3% | 11.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +121.60% |
|---|---|
| Net profit, quarter on quarter | +49.20% |
| Revenue, year on year | +29.80% |
BSE results filing, NSE: BLISSGVS. Figures extracted from the filing.
Bliss GVS Pharma Ltd: key numbers
- Share price
- ₹655.00
- Market cap
- ₹6,968 Cr
- Revenue (annual)
- ₹927.1 Cr
- Net profit (annual)
- ₹129.1 Cr
- P/E (TTM)
- 43.2×Sector 43.8×
- Promoter holding
- 50.07%+15.06% QoQ
- FII holding
- 5.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bliss GVS Pharma Ltd
All →Bliss GVS Pharma Legal & Regulatory
Bliss GVS Pharma was fined Rs. 1,80,000 (excluding GST) by BSE and NSE for failing to appoint a woman director. The fine has been paid to the regulators.
- Value
- ₹0.02 Cr
- From
- BSE Limited and National Stock Exchange of India Limited
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
Bliss GVS Pharma Q2 FY27 Results: Net Profit ₹53.3 Cr, Up 86.4% YoY
Bliss GVS Pharma Ltd reported revenue from operations of ₹313.4 Cr (+28.2% YoY) and net profit of ₹53.3 Cr (+86.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹53.3 Cr · +86.4% YoY
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bliss GVS Pharma Board Meeting Date
Bliss GVS Pharma Ltd scheduled a board meeting for October 29, 2026, to approve the company's unaudited financial results for the quarter ending September 30, 2026.
Bliss GVS Pharma Other Announcement
Bliss GVS Pharma Ltd has filed its quarterly shareholding pattern report for the period ended September 30, 2026.